Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) generates a steady flow of news as a clinical-stage gene therapy company developing treatments for cancer and diabetes. Its updates frequently center on progress in lung cancer trials with Reqorsa Gene Therapy (quaratusugene ozeplasmid) and preclinical advances in its diabetes program, GPX-002.
Investors following GNPX news can expect coverage of clinical trial milestones, such as dose-escalation results, Phase 2 expansion plans, new trial site additions, and peer-reviewed publications from studies like the Acclaim-1 and Acclaim-3 trials in non-small cell and small cell lung cancer. Company releases also highlight regulatory designations, including FDA Fast Track and Orphan Drug status for Reqorsa-based programs.
Another major news theme is preclinical and translational data. Genprex and its collaborators report findings on Reqorsa’s activity in specific lung cancer subtypes, including ALK-EML4-positive NSCLC models, as well as animal data showing TUSC2 upregulation, apoptosis induction, and survival benefits in xenograft studies. For diabetes, news often covers GPX-002 proof-of-concept data in Type 1 and Type 2 diabetes mouse and non-human primate models, including effects on beta-cell function and glucose control.
Genprex also issues corporate and regulatory announcements, such as registered direct offerings, at-the-market programs, warrant-related financings, and patent developments around Reqorsa combinations with PD-1 and PD-L1 antibodies. These items provide context on the company’s capital strategy and intellectual property position.
For readers tracking GNPX, this news stream offers insight into how Genprex’s gene therapy platforms are advancing through research, clinical development, regulatory interactions, and financing activities over time.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, is set to participate in several investor and industry conferences during October 2022. Key events include the Dawson James Securities Annual Small Cap Growth Conference on October 12, where Catherine Vaczy will present, and the Immuno-Oncology Summit, also on October 12, featuring Dr. Mark Berger. Additional presentations at BIO Europe and LD Micro Main Event XV will showcase their innovative therapies targeting cancer and diabetes. For more details, visit Genprex's website.
Genprex, a clinical-stage gene therapy company, will present its innovative therapies for cancer and diabetes at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CFO Ryan Confer will provide a virtual overview accessible on-demand starting September 12 at 7:00 a.m. ET. The company’s lead product, REQORSA™, is being evaluated for lung cancer therapies, supported by the ONCOPREX® Nanoparticle Delivery System. The presentation will be recorded for future viewing on Genprex's website.
Genprex, Inc. (GNPX) announced that the USPTO granted U.S. Patent No: 11,278,592 B2, covering methods for using REQORSA Immunogene Therapy in combination with immune checkpoint inhibitors until 2038. This patent is crucial for protecting their therapy involving Keytruda® for treating non-small cell lung cancer (NSCLC). The ongoing Acclaim-2 Phase 1/2 clinical trial evaluates REQORSA with Keytruda in patients whose cancer progressed after Keytruda treatment, with the Phase 1 portion set to enroll up to 30 patients by mid-2023.
Genprex (NASDAQ: GNPX) announced the Safety Review Committee's approval to advance the Acclaim-1 Phase 1/2 trial of REQORSA™ in combination with Tagrisso® for late-stage non-small cell lung cancer (NSCLC). This decision follows a review of the first cohort, highlighting REQORSA's safety profile. The trial aims to determine the maximum tolerated dose, with enrollment expected to complete the Phase 1 by year-end.
The SRC's decision marks a significant milestone for Genprex, supporting its goal of providing innovative therapies for patients with limited options.
Genprex, Inc. (NASDAQ: GNPX) announces that its manufacturing leadership will present at the Next Generation Lipid-Based Nanoparticles Delivery Summit from July 19-21, 2022, in Boston. Hemant Kumar, Chief Manufacturing and Technology Officer, will discuss innovative gene therapy techniques. Genprex is advancing its lead program targeting non-small cell lung cancer with its proprietary ONCOPREX® Nanoparticle Delivery System. The FDA has granted Fast Track Designation for its lead candidate, REQORSA™, in combination therapies for cancer patients.
On June 2, 2022, Genprex announced its participation in two key investor conferences. The LD Micro Invitational will be held from June 7-9, with Genprex's presentation on June 8 at 4:00 PM PT, led by CFO Ryan Confer. The BIO International Convention is set for June 13-16, with a presentation by EVP Catherine Vaczy on June 14 at 3:30 PM PT. Genprex focuses on gene therapies for cancer and diabetes and uses the ONCOPREX Nanoparticle Delivery System for its lead candidate REQORSA, currently in clinical evaluation for non-small cell lung cancer.
Genprex, Inc. (NASDAQ: GNPX) announced a virtual presentation led by President and CEO Rodney Varner at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. Varner will showcase the company's innovative gene therapies for cancer and diabetes, available on-demand from May 24. Genprex focuses on life-changing therapies, featuring its ONCOPREX® Nanoparticle Delivery System for cancer treatment and its lead candidate, REQORSA™, aimed at non-small cell lung cancer (NSCLC). The FDA has granted Fast Track Designation for REQORSA in combination therapies with Tagrisso® and Keytruda®.
Genprex, Inc. (NASDAQ: GNPX) announced that its Chief Medical Officer, Mark Berger, M.D., will participate in the 33rd Annual Cancer Progress Conference on May 12, 2022. The virtual panel discussion, titled "Into the Unknown – Bringing New Modalities into Solid Tumors," will focus on the positioning of cell-based and emerging immunotherapy platforms in solid tumors. Genprex is a clinical-stage gene therapy company aiming to create innovative therapies for cancer and diabetes, utilizing its ONCOPREX® Nanoparticle Delivery System for its lead product candidate, REQORSA™, targeting non-small cell lung cancer.
Genprex, Inc. (NASDAQ: GNPX) has made significant advancements in its clinical programs in 2022. The company commenced patient treatment in the Phase 1/2 Acclaim-2 trial for non-small cell lung cancer (NSCLC) and received a second Fast Track Designation for its product REQORSA™ Immunogene Therapy. Additionally, Genprex has expanded its pipeline to include small cell lung cancer. CEO Rodney Varner expressed optimism about the company’s future as it pursues innovative gene therapy solutions for patients with serious health conditions.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in key conferences focused on its innovative therapies for cancer and diabetes. The presentations will be held during NobleCon 18 from April 19-21, 2022, with a specific session on April 20 at 11:30 a.m. ET. Additionally, Genprex will feature in the Alliance for Regenerative Medicine's virtual meeting from April 20-22, 2022. These events are crucial for showcasing Genprex's proprietary ONCOPREX® Nanoparticle Delivery System and the lead candidate, REQORSA™, targeting non-small cell lung cancer.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
